Physiologically Based Pharmacokinetic Modeling of Lacosamide in Patients With Hepatic and Renal Impairment and Pediatric Populations to Support Pediatric Dosing Optimization
-
Published:2024-03
Issue:3
Volume:46
Page:258-266
-
ISSN:0149-2918
-
Container-title:Clinical Therapeutics
-
language:en
-
Short-container-title:Clinical Therapeutics
Author:
Zhu Xinyu,
Guo Lingfeng,
Zhang Lei,
Xu YichaoORCID
Reference54 articles.
1. Early identification of refractory epilepsy;Kwan;N Engl J Med,2000
2. Drug-resistant epilepsy and surgery;Sheng;Curr Neuropharmacol,2018
3. Development of new antiepileptic drugs: challenges, incentives, and recent advances;Perucca;Lancet Neurol,2007
4. 30 years of second-generation antiseizure medications: impact and future perspectives;Perucca;Lancet Neurol,2020
5. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial;Baulac;Lancet Neurol,2017